Division News

A recent Northwestern Medicine study published in JAMA has found that one in seven U.S. adults between the ages of 30 and 59 years have a high 30-year risk for cardiovascular disease.

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition with limited treatment options, according to a study published in the journal Circulation.

The use of decision-making aids helped atrial fibrillation patients to be more informed about their care, according to a study published in the British Medical Journal.

Transcatheter heart valve replacement significantly improved outcomes in patients with severe valvular heart diseases compared to standard care alone, according to two recent clinical trials published in the New England Journal of Medicine.

Robert Bonow, MD, the Max and Lilly Goldberg Distinguished Professor of Cardiology and a leading authority on valvular heart disease, has been named a 2024 Distinguished Scientist by the American Heart Association.

Northwestern Medicine investigators have created a novel blood test that identifies adults who may be at increased risk of developing severe respiratory illnesses, according to a recent study published in the American Journal of Respiratory and Critical Care Medicine.

Northwestern Medicine scientists have developed a new way to measure heart contraction and electrical activity in engineered human heart tissues, according to findings published in Science Advances.

The Northwestern University Clinical and Translational Sciences (NUCATS) Institute has received $55 million in National Institutes of Health (NIH) funding to accelerate development, evaluation and implementation of improved healthcare interventions.

Inflamed heart muscles can mount immune responses even in the absence of immune cells, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

Northwestern Medicine investigators have identified novel genetic mechanisms that regulate blood vessel growth in the retina and may also serve as therapeutic targets for retinal vascular disease, according to findings published in Nature Communications.

Feinberg investigators have been selected to lead a $15 million American Heart Association research initiative studying the role of inflammation in heart disease.

As GLP-1 receptor agonist medications like semaglutide have been shown to be effective at helping patients lose weight, scientists are now asking, whether they can treat other conditions where obesity is a risk factor. Most recently, initial studies have shown that they can reduce the risk of cardiovascular disease by reducing overall body weight.

Four Feinberg faculty have been inducted into the American Society for Clinical Investigation (ASCI) and three additional Feinberg faculty have been honored with the ASCI Young Physician-Scientist Award.

Two years after the FDA’s approval of semaglutide for chronic weight management, Northwestern Medicine scientists remain at the forefront of investigating the drug’s potential in helping patients who are overweight or have obesity who also have other preexisting health conditions.

Twelve Feinberg faculty members were named to the 2023 “Highly Cited Researchers” list, published by Clarivate Analytics. The annual list identifies investigators who have demonstrated significant influence in their field through the publication of highly cited publications during the last decade.